EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Rating of “Buy” from Analysts

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) have been given a consensus recommendation of “Buy” by the five analysts that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have covered the stock in the last year is $26.20.

A number of equities analysts have commented on EYPT shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $31.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, September 14th. HC Wainwright cut their price objective on shares of EyePoint Pharmaceuticals from $27.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, November 2nd. Mizuho assumed coverage on shares of EyePoint Pharmaceuticals in a report on Thursday, November 2nd. They set a “buy” rating and a $20.00 price objective on the stock. Chardan Capital restated a “buy” rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday, August 3rd. Finally, StockNews.com assumed coverage on shares of EyePoint Pharmaceuticals in a report on Thursday, October 5th. They set a “hold” rating on the stock.

EyePoint Pharmaceuticals Stock Performance

Shares of EyePoint Pharmaceuticals stock opened at $7.07 on Tuesday. The company has a market capitalization of $249.64 million, a PE ratio of -2.66 and a beta of 1.29. The company has a 50-day simple moving average of $7.83 and a two-hundred day simple moving average of $8.73. EyePoint Pharmaceuticals has a one year low of $2.19 and a one year high of $15.63.

Insiders Place Their Bets

In other EyePoint Pharmaceuticals news, major shareholder Ew Healthcare Partners, L.P. sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $9.90, for a total transaction of $198,000.00. Following the completion of the transaction, the insider now directly owns 3,490,921 shares of the company’s stock, valued at approximately $34,560,117.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders sold 281,114 shares of company stock valued at $3,612,779. 13.05% of the stock is owned by insiders.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. American International Group Inc. grew its stake in shares of EyePoint Pharmaceuticals by 10.2% during the 1st quarter. American International Group Inc. now owns 12,370 shares of the company’s stock worth $150,000 after purchasing an additional 1,142 shares during the period. Royal Bank of Canada grew its stake in shares of EyePoint Pharmaceuticals by 31.9% during the 1st quarter. Royal Bank of Canada now owns 7,934 shares of the company’s stock worth $97,000 after purchasing an additional 1,918 shares during the period. Cubist Systematic Strategies LLC grew its stake in shares of EyePoint Pharmaceuticals by 46.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 6,600 shares of the company’s stock worth $52,000 after purchasing an additional 2,099 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of EyePoint Pharmaceuticals by 99.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock worth $37,000 after purchasing an additional 2,294 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of EyePoint Pharmaceuticals by 3.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 71,282 shares of the company’s stock worth $249,000 after purchasing an additional 2,460 shares during the period. Institutional investors and hedge funds own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc focuses on developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The company's pipeline leverages its proprietary erodible Durasert E technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment, which is in Phase 2 clinical trials.